Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.
Eli
since
auto-detected in 350 stories
70 days ago
Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.
75 days ago
From pills to new uses, here's what Eli Lilly’s top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
76 days ago
Israeli hostage vowed to return to his family – only to find they had been killed
found
a story from The Guardian › International
Eli Sharabi learned his wife and daughters had been killed after his release from captivity in Gaza but is ‘mentally strong’, says British brother-in-law
“Don’t worry, I will be back. Whatever they do…
87 days ago
Sir Keir Starmer slams 'appalling conditions' that Hamas kept Eli Sharabi in as PM reveals his 'dismay' at the Israeli hostage's 'frail condition'
found
a story from The Daily Mail › The Daily Mail
Eli Sharabi, 52, was taken captive from Kibbutz Beeri by the militants during the October 7, 2023 Hamas attack.
British family of Israeli hostage released by Hamas say the 'spark is gone from his eyes' after 491 DAYS in captivity
found
a story from The Daily Mail › The Daily Mail
Eli Sharabi was taken captive from Kibbutz Beeri by the militants during the October 7, 2023 Hamas attack.
89 days ago
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Zepbound and Mounjaro have now underperformed expectations for two straight quarters.
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Zepbound and Mounjaro have now underperformed expectations for two straight quarters.
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
|← first ← previous page 3 of 4 next → last →|